查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1393487

杜氏肌肉营养不良症治疗的全球市场 - 产业趋势与预测（截至 2030 年）

Global Duchenne Muscular Dystrophy Treatment Market - Industry Trends and Forecast to 2030
出版日期: | 出版商: Data Bridge Market Research | 英文 343 Pages | 商品交期: 请询问到货日

价格

全球杜氏肌肉营养不良症治疗市场规模预计将从 2022 年的 2,595,090,000 美元增至 2030 年的 8,654,688,510 美元，2023 年至 2030 年复合年增长率为 16.8%。

本报告研究和分析了全球杜氏肌肉营养不良症治疗市场，提供行业趋势和预测、驱动和限制因素以及公司趋势等资讯。

目录

第 1 章简介

第 2 章市场区隔

第 3 章执行摘要

第 4 章重要考量

  • PESTEL模型
  • 波特五力分析模型
  • 价格分析

第 5 章全球杜氏肌肉营养不良症治疗市场：监管

  • 美国法规
  • 欧洲法规
  • 澳洲法规
  • 南非法规
  • 巴西法规

第 6 章市场概论

  • 促进因素
    • 杜氏肌肉营养不良 (DMD) 疾病的盛行率和影响不断增加
    • 介绍DMD疾病的新治疗方法
    • 提高对 DMD 治疗的认识
    • 临床试验的增加是近年来的趋势
  • 抑制因素
    • 由于缺乏先进技术，DMD 治疗的可用性有限
    • DMD 疾病的治疗费用高昂
  • 机会
    • 增加医疗基础设施的开发和投资
    • 病人越来越偏好有效的个人化治疗
    • 主要市场参与者的策略性举措
    • 病患权益团体对监理审批流程的支持
  • 作业
    • DMD 诊断缺乏标准化
    • 关于永久改变病人遗传密码的伦理考虑

第 7 章全球杜氏肌肉营养不良症治疗市场：依治疗类型

  • 摘要
  • 基于分子的治疗
    • 反义寡核甘酸疗法
  • 无义突变
  • 类固醇治疗
    • 普赖鬆
    • Deflazacort
  • 其他

第 8 章全球杜氏肌肉营养不良症治疗市场：依治疗方法分类

  • 摘要
  • 外显子跳跃法
    • 多外显子跳跃法
    • 单外显子跳跃法
  • 突变抑制
  • 肌肉营养不良蛋白标靶治疗
    • 基因治疗
    • 细胞疗法

第 9 章全球杜氏肌肉营养不良症治疗市场：依给药途径划分

  • 摘要
  • 注射用
  • 口服
  • 其他

第 10 章全球杜氏肌肉营养不良症治疗市场：依最终使用者划分

  • 摘要
  • 医院
  • 专科诊所
  • 居家护理
  • 其他

第 11 章全球杜氏肌肉营养不良症治疗市场：依通路划分

  • 摘要
  • 医院药房
  • 零售药局
  • 网路药局

第 12 章全球杜氏肌肉营养不良症治疗市场：按地区

  • 摘要
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 土耳其
    • 比利时
    • 荷兰
    • 瑞士
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳大利亚
    • 新加坡
    • 泰国
    • 马来西亚
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯联合大公国
    • 埃及
    • 以色列
    • 其他中东/非洲

第 13 章全球杜氏肌肉营养不良症治疗市场与公司状况

  • 公司股票分析：全球

第 14 章北美杜氏肌肉营养不良症治疗市场及企业状况

  • 公司股票分析：北美

第 15 章欧洲杜氏肌肉营养不良症治疗市场与公司状况

  • 公司股票分析：欧洲

第 16 章亚太地区杜氏肌肉营养不良症治疗市场及企业状况

  • 公司股票分析：亚太地区

第 17 章 SWOT 分析

第 18 章公司简介

  • SAREPTA THERAPEUTICS, INC.
  • F. HOFFMANN-LA ROCHE LTD
  • PTC THERAPEUTICS.
  • PFIZER INC.
  • AKASHI RX
  • AVIDITY BIOSCIENCES
  • BIOMARIN
  • CAPRICOR THERAPEUTICS, INC.
  • DYNE THERAPEUTICS
  • FIBROGEN, INC.
  • ITALFARMACO S.P.A.
  • NS PHARMA, INC.
  • REVERAGEN BIOPHARMA, INC.
  • SANTHERA PHARMACEUTICALS
  • TAIHO PHARMACEUTICAL CO., LTD.
  • SOLID BIOSCIENCES INC.
  • STEALTH BIOTHERAPEUTICS INC

第 19 章调查

第 20 章相关报告

The global duchenne muscular dystrophy treatment market is expected to reach USD 8,654,688.51 thousand by 2030 from USD 2,595,090.00 thousand in 2022, growing at a CAGR of 16.8% in the forecast period of 2023 to 2030.

Market Segmentation

Global Duchenne Muscular Dystrophy Treatment Market, By Treatment Type (Molecular-Based Therapies, Steroid Therapy, and Others), Therapy (Exon Skipping Approach, Mutation Suppression, and Dystrophin-Targeted Therapies), Route of Administration (Oral, Parenteral, and Others), End User (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2030.

Overview of Global Duchenne Muscular Dystrophy Treatment Market Dynamics

  • Driver
  • Increasing prevalence and impact of Duchenne Muscular Dystrophy (DMD) disease
  • Restraint
  • High treatment cost of DMD disorder
  • Opportunity
  • Strategic initiatives by key market players

Market Players

Some of the key market players for global duchenne muscular dystrophy treatment market are:

  • Sarepta Therapeutics, Inc.
  • Solid Biosciences Inc.
  • Capricor Therapeutics, Inc.
  • Dyne Therapeutics
  • BioMarin
  • Stealth BioTherapeutics Inc
  • Avidity Biosciences
  • ReveraGen
  • BioPharma, Inc.
  • TAIHO PHARMACEUTICAL CO., LTD.
  • Akashi RX
  • ITALFARMACO S.p.
  • NS Pharma, Inc.
  • PTC Therapeutics.
  • Pfizer Inc.
  • FibroGen, Inc.
  • SANTHERA PHARMACEUTICALS
  • F. Hoffmann-La Roche Ltd

TABLE OF CONTENTS

1 INTRODUCTION 45

  • 1.1 OBJECTIVES OF THE STUDY 45
  • 1.2 MARKET DEFINITION 45
  • 1.3 OVERVIEW OF THE GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET 45
  • 1.4 CURRENCY AND PRICING 47
  • 1.5 LIMITATIONS 47
  • 1.6 MARKETS COVERED 47

2 MARKET SEGMENTATION 49

  • 2.1 MARKETS COVERED 49
  • 2.2 GEOGRAPHICAL SCOPE 50
  • 2.3 YEARS CONSIDERED FOR THE STUDY 51
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 52
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 55
  • 2.6 MULTIVARIATE MODELLING 56
  • 2.7 TREATMENT TYPE SEGMENT LIFELINE CURVE 56
  • 2.8 MARKET END USER COVERAGE GRID 57
  • 2.9 DBMR MARKET POSITION GRID 58
  • 2.10 VENDOR SHARE ANALYSIS 59
  • 2.11 SECONDARY SOURCES 60
  • 2.12 ASSUMPTIONS 60

3 EXECUTIVE SUMMARY 61

4 PREMIUM INSIGHTS 63

  • 4.1 PESTEL'S MODEL 64
  • 4.2 PORTER'S FIVE FORCES MODEL 65
  • 4.3 PRICING ANALYSIS 65

5 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: REGULATIONS 67

  • 5.1 REGULATIONS IN U.S. 67
  • 5.2 REGULATTIONS IN EUROPE 68
  • 5.3 REGULATTIONS IN AUSTRALIA 68
  • 5.4 REGULATIONS IN SOUTH AFRICA 68
  • 5.5 REGULATIONS IN BRAZIL 69 

6 MARKET OVERVIEW 70

  • 6.1 DRIVERS 72
    • 6.1.1 INCREASING PREVALENCE AND IMPACT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) DISEASE 72
    • 6.1.2 INTRODUCTION OF NOVEL THERAPIES FOR DMD DISORDER 72
    • 6.1.3 RISING AWARENESS FOR DMD TREATMENTS 73
    • 6.1.4 INCREASE IN THE NUMBER OF CLINICAL TRIALS IS A RECENT TREND 74
  • 6.2 RESTRAINTS 75
    • 6.2.1 LIMITED AVAILABILITY OF DMD TREATMENTS DUE TO LACK OF ADVANCE TECHNOLOGY 75
    • 6.2.2 HIGH TREATMENT COST OF DMD DISORDER 76
  • 6.3 OPPORTUNITIES 77
    • 6.3.1 DEVELOPMENT OF HEALTHCARE INFRASTRUCTURE AND INCREASING INVESTMENT 77
    • 6.3.2 RISING PATIENT INCLINATION TOWARDS PERSONALIZED AND EFFECTIVE THERAPIES 77
    • 6.3.3 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYERS 78
    • 6.3.4 SUPPORT FROM PATIENT ADVOCACY GROUPS ON THE REGULATORY APPROVAL PROCESS 78
  • 6.4 CHALLENGES 79
    • 6.4.1 LACK OF STANDARDIZATION IN DMD DIAGNOSIS 79
    • 6.4.2 ETHICAL CONSIDERATIONS RELATED TO PERMANENT ALTERATION OF A PATIENT'S GENETIC CODE 80

7 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE 81

  • 7.1 OVERVIEW 82
  • 7.2 MOLECULAR-BASED THERAPIES 85
    • 7.2.1 ANTISENSE OLIGONUCLEOTIDE THERAPY 86
      • 7.2.1.1 EXONDYS 51 86
      • 7.2.1.2 AMONDYS 45 87
      • 7.2.1.3 VYONDYS 53 87
  • 7.3 NONSENSE MUTATION 87
      • 7.3.1.1 Translarna 87
  • 7.4 STEROID THERAPY 88
    • 7.4.1 PREDNISONE 88
    • 7.4.2 DEFLAZACORT 88
  • 7.5 OTHERS 89 

8 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY 90

  • 8.1 OVERVIEW 91
  • 8.2 EXON SKIPPING APPROACH 94
    • 8.2.1 MULTI-EXON SKIPPING APPROACH 94
    • 8.2.2 SINGLE-EXON SKIPPING APPROACH 95
  • 8.3 MUTATION SUPPRESSION 95
  • 8.4 DYSTROPHIN-TARGETED THERAPIES 96
    • 8.4.1 GENE THERAPIES 96
    • 8.4.2 CELL THERAPIES 97
      • 8.4.2.1 Gene Editing 97
      • 8.4.2.2 Gene Addition 97

9 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 98

  • 9.1 OVERVIEW 99
  • 9.2 PARENTERAL 102
  • 9.3 ORAL 103
  • 9.4 OTHERS 104

10 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER 105

  • 10.1 OVERVIEW 106
  • 10.2 HOSPITALS 109
  • 10.3 SPECIALTY CLINICS 110
  • 10.4 HOMECARE 111
  • 10.5 OTHERS 112

11 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL 113

  • 11.1 OVERVIEW 114
  • 11.2 HOSPITAL PHARMACY 117
  • 11.3 RETAIL PHARMACY 118
  • 11.4 ONLINE PHARMACY 119

12 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION 120

  • 12.1 OVERVIEW 121
  • 12.2 NORTH AMERICA 124
    • 12.2.1 U.S. 129
    • 12.2.2 CANADA 134
    • 12.2.3 MEXICO 139
  • 12.3 EUROPE 145
    • 12.3.1 GERMANY 151
    • 12.3.2 FRANCE 156
    • 12.3.3 U.K. 161
    • 12.3.4 ITALY 166
    • 12.3.5 SPAIN 171
    • 12.3.6 RUSSIA 176
    • 12.3.7 TURKEY 181
    • 12.3.8 BELGIUM 186
    • 12.3.9 NETHERLANDS 191
    • 12.3.10 SWITZERLAND 196
    • 12.3.11 REST OF EUROPE 201
  • 12.4 ASIA-PACIFIC 202
    • 12.4.1 CHINA 207
    • 12.4.2 JAPAN 212
    • 12.4.3 INDIA 217
    • 12.4.4 SOUTH KOREA 222
    • 12.4.5 AUSTRALIA 227
    • 12.4.6 SINGAPORE 232
    • 12.4.7 THAILAND 237
    • 12.4.8 MALAYSIA 242
    • 12.4.9 INDONESIA 247
    • 12.4.10 PHILIPPINES 252
    • 12.4.11 REST OF ASIA-PACIFIC 257
  • 12.5 SOUTH AMERICA 258
    • 12.5.1 BRAZIL 263
    • 12.5.2 ARGENTINA 268
    • 12.5.3 REST OF SOUTH AMERICA 273
  • 12.6 MIDDLE EAST AND AFRICA 274
    • 12.6.1 SOUTH AFRICA 279
    • 12.6.2 SAUDI ARABIA 284
    • 12.6.3 U.A.E 289
    • 12.6.4 EGYPT 294
    • 12.6.5 ISRAEL 299
    • 12.6.6 REST OF MIDDLE EAST AND AFRICA 304

13 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, COMPANY LANDSCAPE 305

  • 13.1 COMPANY SHARE ANALYSIS: GLOBAL 305

14 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, COMPANY LANDSCAPE 306

  • 14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 306

15 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, COMPANY LANDSCAPE 307

  • 15.1 COMPANY SHARE ANALYSIS: EUROPE 307

16 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, COMPANY LANDSCAPE 308

  • 16.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 308

17 SWOT ANALYSIS 309

18 COMPANY PROFILES 310

  • 18.1 SAREPTA THERAPEUTICS, INC. 310
    • 18.1.1 COMPANY SNAPSHOT 310
    • 18.1.1 REVENUE ANALYSIS 311
    • 18.1.2 COMPANY SHARE ANALYSIS 311
    • 18.1.3 PRODUCT PORTFOLIO 312
    • 18.1.4 PIPELINE PORTFOLIO 312
    • 18.1.5 RECENT DEVELOPMENTS 312
  • 18.2 F. HOFFMANN-LA ROCHE LTD 314
    • 18.2.1 COMPANY SNAPSHOT 314
    • 18.2.2 REVENUE ANALYSIS 314
    • 18.2.3 COMPANY SHARE ANALYSIS 315
    • 18.2.4 PRODUCT PORTFOLIO 315
    • 18.2.5 PIPELINE PORTFOLIO 315
    • 18.2.6 RECENT DEVELOPMENTS 315
  • 18.3 PTC THERAPEUTICS. 316
    • 18.3.1 COMPANY SNAPSHOT 316
    • 18.3.2 REVENUE ANALYSIS 316
    • 18.3.3 COMPANY SHARE ANALYSIS 317
    • 18.3.4 PRODUCT PORTFOLIO 317
    • 18.3.5 RECENT DEVELOPMENT 317
  • 18.4 PFIZER INC. 318
    • 18.4.1 COMPANY SNAPSHOT 318
    • 18.4.2 REVENUE ANALYSIS 318
    • 18.4.3 COMPANY SHARE ANALYSIS 319
    • 18.4.4 PIPELINE PORTFOLIO 319
    • 18.4.5 PRODUCT PORTFOLIO 319
    • 18.4.6 RECENT DEVELOPMENT 319
  • 18.5 AKASHI RX 320
    • 18.5.1 COMPANY SNAPSHOT 320
    • 18.5.2 PIPELINE PORTFOLIO 320
    • 18.5.3 RECENT DEVELOPMENTS 320
  • 18.6 AVIDITY BIOSCIENCES 321
    • 18.6.1 COMPANY SNAPSHOT 321
    • 18.6.2 REVENUE ANALYSIS 321
    • 18.6.3 PIPELINE PORTFOLIO 322
    • 18.6.4 RECENT DEVELOPMENTS 322
  • 18.7 BIOMARIN 323
    • 18.7.1 COMPANY SNAPSHOT 323
    • 18.7.2 REVENUE ANALYSIS 323
    • 18.7.3 PIPELINE PORTFOLIO 324
    • 18.7.4 RECENT DEVELOPMENTS 324
  • 18.8 CAPRICOR THERAPEUTICS, INC. 325
    • 18.8.1 COMPANY SNAPSHOT 325
    • 18.8.2 PIPELINE PORTFOLIO 325
    • 18.8.3 RECENT DEVELOPMENTS 326
  • 18.9 DYNE THERAPEUTICS 327
    • 18.9.1 COMPANY SNAPSHOT 327
    • 18.9.2 PIPELINE PORTFOLIO 327
    • 18.9.3 RECENT DEVELOPMENTS 328
  • 18.10 FIBROGEN, INC. 329
    • 18.10.1 COMPANY SNAPSHOT 329
    • 18.10.2 REVENUE ANALYSIS 329
    • 18.10.3 PIPELINE PORTFOLIO 330
    • 18.10.4 RECENT DEVELOPMENT 330
  • 18.11 ITALFARMACO S.P.A. 331
    • 18.11.1 COMPANY SNAPSHOT 331
    • 18.11.2 PIPELINE PORTFOLIO 331
    • 18.11.3 RECENT DEVELOPMENT 331
  • 18.12 NS PHARMA, INC. 332
    • 18.12.1 COMPANY SNAPSHOT 332
    • 18.12.2 PIPELINE PORTFOLIO 332
    • 18.12.3 RECENT DEVELOPMENTS 333
  • 18.13 REVERAGEN BIOPHARMA, INC. 334
    • 18.13.1 COMPANY SNAPSHOT 334
    • 18.13.2 PIPELINE PORTFOLIO 334
    • 18.13.3 RECENT DEVELOPMENT 334
  • 18.14 SANTHERA PHARMACEUTICALS 335
    • 18.14.1 COMPANY SNAPSHOT 335
    • 18.14.2 REVENUE ANALYSIS 335
    • 18.14.3 PIPELINE PORTFOLIO 336
    • 18.14.4 RECENT DEVELOPMENT 336
  • 18.15 TAIHO PHARMACEUTICAL CO., LTD. 337
    • 18.15.1 COMPANY SNAPSHOT 337
    • 18.15.2 PIPELINE PORTFOLIO 337
    • 18.15.3 RECENT DEVELOPMENTS 337
  • 18.16 SOLID BIOSCIENCES INC. 338
    • 18.16.1 COMPANY SNAPSHOT 338
    • 18.16.2 PIPELINE PORTFOLIO 338
    • 18.16.3 RECENT DEVELOPMENT 338
  • 18.17 STEALTH BIOTHERAPEUTICS INC 339
    • 18.17.1 COMPANY SNAPSHOT 339
    • 18.17.2 PIPELINE PORTFOLIO 339
    • 18.17.3 RECENT DEVELOPMENT 339

19 QUESTIONNAIRE 340

20 RELATED REPORTS 343

LIST OF TABLES

  • TABLE 1 LIST OF PRICES FOR APPROVED DRUGS OF THE GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET 66
  • TABLE 2 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE , 2021-2030 (USD THOUSAND) 85
  • TABLE 3 GLOBAL MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 85
  • TABLE 4 GLOBAL MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 86
  • TABLE 5 GLOBAL ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 86
  • TABLE 6 GLOBAL NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 87
  • TABLE 7 GLOBAL STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 88
  • TABLE 8 GLOBAL STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 88
  • TABLE 9 GLOBAL OTHERS IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 89
  • TABLE 10 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 93
  • TABLE 11 GLOBAL EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 94
  • TABLE 12 GLOBAL EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 94
  • TABLE 13 GLOBAL MUTATION SUPPRESSION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 95
  • TABLE 14 GLOBAL DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 96
  • TABLE 15 GLOBAL DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 96
  • TABLE 16 GLOBAL CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 97
  • TABLE 17 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2021-2030 (USD THOUSAND) 101
  • TABLE 18 GLOBAL PARENTERAL IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 102
  • TABLE 19 GLOBAL ORAL IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 103
  • TABLE 20 GLOBAL OTHERS IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 104
  • TABLE 21 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USERS, 2021-2030 (USD THOUSAND) 108
  • TABLE 22 GLOBAL HOSPITALS IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 109
  • TABLE 23 GLOBAL SPECIALITY CLINICS IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 110
  • TABLE 24 GLOBAL HOMECARE IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 111
  • TABLE 25 GLOBAL OTHERS IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 112
  • TABLE 26 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 117
  • TABLE 27 GLOBAL HOSPITAL PHARMACY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 117
  • TABLE 28 GLOBAL RETAIL PHARMACY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 118
  • TABLE 29 GLOBAL ONLINE PHARMACY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 119
  • TABLE 30 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 123
  • TABLE 31 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) COUNTRY 124
  • TABLE 32 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 124
  • TABLE 33 NORTH AMERICA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 124
  • TABLE 34 NORTH AMERICA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 125
  • TABLE 35 NORTH AMERICA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 125
  • TABLE 36 NORTH AMERICA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 125
  • TABLE 37 NORTH AMERICA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 125
  • TABLE 38 NORTH AMERICA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 126
  • TABLE 39 NORTH AMERICA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 126
  • TABLE 40 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 126
  • TABLE 41 NORTH AMERICA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 126
  • TABLE 42 NORTH AMERICA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 127
  • TABLE 43 NORTH AMERICA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 127
  • TABLE 44 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 127
  • TABLE 45 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 128
  • TABLE 46 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 128
  • TABLE 47 U.S. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 129
  • TABLE 48 U.S. MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 129
  • TABLE 49 U.S. ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 129
  • TABLE 50 U.S. ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 130
  • TABLE 51 U.S. ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 130
  • TABLE 52 U.S. NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 130
  • TABLE 53 U.S. NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 130
  • TABLE 54 U.S. NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 131
  • TABLE 55 U.S. STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 131
  • TABLE 56 U.S. STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 131
  • TABLE 57 U.S. STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 131
  • TABLE 58 U.S.DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 132
  • TABLE 59 U.S. EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 132
  • TABLE 60 U.S. DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 132
  • TABLE 61 U.S. CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 132
  • TABLE 62 U.S. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 133
  • TABLE 63 U.S. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 133
  • TABLE 64 U.S. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 133
  • TABLE 65 CANADA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 134
  • TABLE 66 CANADA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 134
  • TABLE 67 CANADA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 134
  • TABLE 68 CANADA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 135
  • TABLE 69 CANADA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 135
  • TABLE 70 CANADA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 135
  • TABLE 71 CANADA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 135
  • TABLE 72 CANADA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 136
  • TABLE 73 CANADA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 136
  • TABLE 74 CANADA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 136
  • TABLE 75 CANADA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 136
  • TABLE 76 CANADA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 137
  • TABLE 77 CANADA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 137
  • TABLE 78 CANADA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 137
  • TABLE 79 CANADA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 137
  • TABLE 80 CANADA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 138
  • TABLE 81 CANADA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 138
  • TABLE 82 CANADA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 138
  • TABLE 83 MEXICO DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 139
  • TABLE 84 MEXICO MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 139
  • TABLE 85 MEXICO ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 139
  • TABLE 86 MEXICO ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 140
  • TABLE 87 MEXICO ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 140
  • TABLE 88 MEXICO NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 140
  • TABLE 89 MEXICO NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 140
  • TABLE 90 MEXICO NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 141
  • TABLE 91 MEXICO STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 141
  • TABLE 92 MEXICO STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 141
  • TABLE 93 MEXICO STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 141
  • TABLE 94 MEXICO DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 142
  • TABLE 95 MEXICO EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 142
  • TABLE 96 MEXICO DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 142
  • TABLE 97 MEXICO CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 143
  • TABLE 98 MEXICO DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 143
  • TABLE 99 MEXICO DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 143
  • TABLE 100 MEXICO DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 144
  • TABLE 101 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 145
  • TABLE 102 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 146
  • TABLE 103 EUROPE MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 146
  • TABLE 104 EUROPE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 146
  • TABLE 105 EUROPE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 147
  • TABLE 106 EUROPE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 147
  • TABLE 107 EUROPE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 147
  • TABLE 108 EUROPE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 147
  • TABLE 109 EUROPE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 148
  • TABLE 110 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 148
  • TABLE 111 EUROPE EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 148
  • TABLE 112 EUROPE DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 149
  • TABLE 113 EUROPE CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 149
  • TABLE 114 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 149
  • TABLE 115 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 150
  • TABLE 116 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 150
  • TABLE 117 GERMANY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 151
  • TABLE 118 GERMANY MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 151
  • TABLE 119 GERMANY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 151
  • TABLE 120 GERMANY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 152
  • TABLE 121 GERMANY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 152
  • TABLE 122 GERMANY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 152
  • TABLE 123 GERMANY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 152
  • TABLE 124 GERMANY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 153
  • TABLE 125 GERMANY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 153
  • TABLE 126 GERMANY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 153
  • TABLE 127 GERMANY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 153
  • TABLE 128 GERMANY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 154
  • TABLE 129 GERMANY EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 154
  • TABLE 130 GERMANY DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 154
  • TABLE 131 GERMANY CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 154
  • TABLE 132 GERMANY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 155
  • TABLE 133 GERMANY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 155
  • TABLE 134 GERMANY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 155
  • TABLE 135 FRANCE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 156
  • TABLE 136 FRANCE MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 156
  • TABLE 137 FRANCE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 156
  • TABLE 138 FRANCE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 157
  • TABLE 139 FRANCE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 157
  • TABLE 140 FRANCE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 157
  • TABLE 141 FRANCE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 157
  • TABLE 142 FRANCE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 158
  • TABLE 143 FRANCE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 158
  • TABLE 144 FRANCE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 158
  • TABLE 145 FRANCE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 158
  • TABLE 146 FRANCE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 159
  • TABLE 147 FRANCE EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 159
  • TABLE 148 FRANCE DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 159
  • TABLE 149 FRANCE CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 159
  • TABLE 150 FRANCE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 160
  • TABLE 151 FRANCE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 160
  • TABLE 152 FRANCE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 160
  • TABLE 153 U.K. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 161
  • TABLE 154 U.K. MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 161
  • TABLE 155 U.K. ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 161
  • TABLE 156 U.K. ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 162
  • TABLE 157 U.K. ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 162
  • TABLE 158 U.K. NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 162
  • TABLE 159 U.K. NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 162
  • TABLE 160 U.K. NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 163
  • TABLE 161 U.K. STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 163
  • TABLE 162 U.K. STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 163
  • TABLE 163 U.K. STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 163
  • TABLE 164 U.K. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 164
  • TABLE 165 U.K. EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 164
  • TABLE 166 U.K. DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 164
  • TABLE 167 U.K. CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 164
  • TABLE 168 U.K. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 165
  • TABLE 169 U.K. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 165
  • TABLE 170 U.K. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 165
  • TABLE 171 ITALY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 166
  • TABLE 172 ITALY MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 166
  • TABLE 173 ITALY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 166
  • TABLE 174 ITALY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 167
  • TABLE 175 ITALY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 167
  • TABLE 176 ITALY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 167
  • TABLE 177 ITALY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 167
  • TABLE 178 ITALY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 168
  • TABLE 179 ITALY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 168
  • TABLE 180 ITALY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 168
  • TABLE 181 ITALY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 168
  • TABLE 182 ITALYDUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 169
  • TABLE 183 ITALY EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 169
  • TABLE 184 ITALY DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 169
  • TABLE 185 ITALY CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 169
  • TABLE 186 ITALY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 170
  • TABLE 187 ITALY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 170
  • TABLE 188 ITALY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 170
  • TABLE 189 SPAIN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 171
  • TABLE 190 SPAIN MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 171
  • TABLE 191 SPAIN ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 171
  • TABLE 192 SPAIN ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 172
  • TABLE 193 SPAIN ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 172
  • TABLE 194 SPAIN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 172
  • TABLE 195 SPAIN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 172
  • TABLE 196 SPAIN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 173
  • TABLE 197 SPAIN STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 173
  • TABLE 198 SPAIN STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 173
  • TABLE 199 SPAIN STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 173
  • TABLE 200 SPAIN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 174
  • TABLE 201 SPAIN EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 174
  • TABLE 202 SPAIN DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 174
  • TABLE 203 SPAIN CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 174
  • TABLE 204 SPAIN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 175
  • TABLE 205 SPAIN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 175
  • TABLE 206 SPAIN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 175
  • TABLE 207 RUSSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 176
  • TABLE 208 RUSSIA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 176
  • TABLE 209 RUSSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 176
  • TABLE 210 RUSSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 177
  • TABLE 211 RUSSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 177
  • TABLE 212 RUSSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 177
  • TABLE 213 RUSSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 177
  • TABLE 214 RUSSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 178
  • TABLE 215 RUSSIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 178
  • TABLE 216 RUSSIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 178
  • TABLE 217 RUSSIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 178
  • TABLE 218 RUSSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 179
  • TABLE 219 RUSSIA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 179
  • TABLE 220 RUSSIA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 179
  • TABLE 221 RUSSIA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 179
  • TABLE 222 RUSSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 180
  • TABLE 223 RUSSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 180
  • TABLE 224 RUSSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 180
  • TABLE 225 TURKEY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 181
  • TABLE 226 TURKEY MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 181
  • TABLE 227 TURKEY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 181
  • TABLE 228 TURKEY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 182
  • TABLE 229 TURKEY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 182
  • TABLE 230 TURKEY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 182
  • TABLE 231 TURKEY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 182
  • TABLE 232 TURKEY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 183
  • TABLE 233 TURKEY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 183
  • TABLE 234 TURKEY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 183
  • TABLE 235 TURKEY STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 183
  • TABLE 236 TURKEY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 184
  • TABLE 237 TURKEY EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 184
  • TABLE 238 TURKEY DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 184
  • TABLE 239 TURKEY CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 184
  • TABLE 240 TURKEY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 185
  • TABLE 241 TURKEY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 185
  • TABLE 242 TURKEY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 185
  • TABLE 243 BELGIUM DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 186
  • TABLE 244 BELGIUM MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 186
  • TABLE 245 BELGIUM ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 186
  • TABLE 246 BELGIUM ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 187
  • TABLE 247 BELGIUM ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 187
  • TABLE 248 BELGIUM NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 187
  • TABLE 249 BELGIUM NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 187
  • TABLE 250 BELGIUM NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 188
  • TABLE 251 BELGIUM STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 188
  • TABLE 252 BELGIUM STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 188
  • TABLE 253 BELGIUM STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 188
  • TABLE 254 BELGIUM DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 189
  • TABLE 255 BELGIUM EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 189
  • TABLE 256 BELGIUM DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 189
  • TABLE 257 BELGIUM CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 189
  • TABLE 258 BELGIUM DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 190
  • TABLE 259 BELGIUM DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 190
  • TABLE 260 BELGIUM DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 190
  • TABLE 261 NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 191
  • TABLE 262 NETHERLANDS MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 191
  • TABLE 263 NETHERLANDS ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 191
  • TABLE 264 NETHERLANDS ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 192
  • TABLE 265 NETHERLANDS ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 192
  • TABLE 266 NETHERLANDS NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 192
  • TABLE 267 NETHERLANDS NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 192
  • TABLE 268 NETHERLANDS NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 193
  • TABLE 269 NETHERLANDS STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 193
  • TABLE 270 NETHERLANDS STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 193
  • TABLE 271 NETHERLANDS STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 193
  • TABLE 272 NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 194
  • TABLE 273 NETHERLANDS EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 194
  • TABLE 274 NETHERLANDS DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 194
  • TABLE 275 NETHERLANDS CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 194
  • TABLE 276 NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 195
  • TABLE 277 NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 195
  • TABLE 278 NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 195
  • TABLE 279 SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 196
  • TABLE 280 SWITZERLAND MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 196
  • TABLE 281 SWITZERLAND ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 196
  • TABLE 282 SWITZERLAND ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 197
  • TABLE 283 SWITZERLAND ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 197
  • TABLE 284 SWITZERLAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 197
  • TABLE 285 SWITZERLAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 197
  • TABLE 286 SWITZERLAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 198
  • TABLE 287 SWITZERLAND STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 198
  • TABLE 288 SWITZERLAND STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 198
  • TABLE 289 SWITZERLAND STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 198
  • TABLE 290 SWITZERLANDDUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 199
  • TABLE 291 SWITZERLAND EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 199
  • TABLE 292 SWITZERLAND DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 199
  • TABLE 293 SWITZERLAND CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 199
  • TABLE 294 SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 200
  • TABLE 295 SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 200
  • TABLE 296 SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 200
  • TABLE 297 REST OF EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 201
  • TABLE 298 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 202
  • TABLE 299 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 202
  • TABLE 300 ASIA-PACIFIC MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 203
  • TABLE 301 ASIA-PACIFIC ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 203
  • TABLE 302 ASIA-PACIFIC ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 203
  • TABLE 303 ASIA-PACIFIC NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 204
  • TABLE 304 ASIA-PACIFIC NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 204
  • TABLE 305 ASIA-PACIFIC STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 204
  • TABLE 306 ASIA-PACIFIC STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 204
  • TABLE 307 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 205
  • TABLE 308 ASIA-PACIFIC EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 205
  • TABLE 309 ASIA-PACIFIC DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 205
  • TABLE 310 ASIA-PACIFIC CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 205
  • TABLE 311 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 206
  • TABLE 312 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 206
  • TABLE 313 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 206
  • TABLE 314 CHINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 207
  • TABLE 315 CHINA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 207
  • TABLE 316 CHINA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 207
  • TABLE 317 CHINA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 208
  • TABLE 318 CHINA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 208
  • TABLE 319 CHINA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 208
  • TABLE 320 CHINA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 208
  • TABLE 321 CHINA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 209
  • TABLE 322 CHINA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 209
  • TABLE 323 CHINA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 209
  • TABLE 324 CHINA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 209
  • TABLE 325 CHINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 210
  • TABLE 326 CHINA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 210
  • TABLE 327 CHINA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 210
  • TABLE 328 CHINA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 210
  • TABLE 329 CHINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 211
  • TABLE 330 CHINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 211
  • TABLE 331 CHINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 211
  • TABLE 332 JAPAN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 212
  • TABLE 333 JAPAN MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 212
  • TABLE 334 JAPAN ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 212
  • TABLE 335 JAPAN ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 213
  • TABLE 336 JAPAN ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 213
  • TABLE 337 JAPAN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 213
  • TABLE 338 JAPAN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 213
  • TABLE 339 JAPAN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 214
  • TABLE 340 JAPAN STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 214
  • TABLE 341 JAPAN STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 214
  • TABLE 342 JAPAN STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 214
  • TABLE 343 JAPAN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 215
  • TABLE 344 JAPAN EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 215
  • TABLE 345 JAPAN DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 215
  • TABLE 346 JAPAN CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 215
  • TABLE 347 JAPAN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 216
  • TABLE 348 JAPAN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 216
  • TABLE 349 JAPAN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 216
  • TABLE 350 INDIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 217
  • TABLE 351 INDIA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 217
  • TABLE 352 INDIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 217
  • TABLE 353 INDIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 218
  • TABLE 354 INDIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 218
  • TABLE 355 INDIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 218
  • TABLE 356 INDIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 218
  • TABLE 357 INDIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 219
  • TABLE 358 INDIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 219
  • TABLE 359 INDIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 219
  • TABLE 360 INDIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 219
  • TABLE 361 INDIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 220
  • TABLE 362 INDIA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 220
  • TABLE 363 INDIA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 220
  • TABLE 364 INDIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 221
  • TABLE 365 INDIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 221
  • TABLE 366 INDIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 221
  • TABLE 367 SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 222
  • TABLE 368 SOUTH KOREA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 222
  • TABLE 369 SOUTH KOREA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 222
  • TABLE 370 SOUTH KOREA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 223
  • TABLE 371 SOUTH KOREA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 223
  • TABLE 372 SOUTH KOREA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 223
  • TABLE 373 SOUTH KOREA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 223
  • TABLE 374 SOUTH KOREA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 224
  • TABLE 375 SOUTH KOREA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 224
  • TABLE 376 SOUTH KOREA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 224
  • TABLE 377 SOUTH KOREA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 224
  • TABLE 378 SOUTH KOREADUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 225
  • TABLE 379 SOUTH KOREA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 225
  • TABLE 380 SOUTH KOREA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 225
  • TABLE 381 SOUTH KOREA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 225
  • TABLE 382 SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 226
  • TABLE 383 SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 226
  • TABLE 384 SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 226
  • TABLE 385 AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 227
  • TABLE 386 AUSTRALIA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 227
  • TABLE 387 AUSTRALIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 227
  • TABLE 388 AUSTRALIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 228
  • TABLE 389 AUSTRALIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 228
  • TABLE 390 AUSTRALIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 228
  • TABLE 391 AUSTRALIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 228
  • TABLE 392 AUSTRALIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 229
  • TABLE 393 AUSTRALIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 229
  • TABLE 394 AUSTRALIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 229
  • TABLE 395 AUSTRALIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 229
  • TABLE 396 AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 230
  • TABLE 397 AUSTRALIA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 230
  • TABLE 398 AUSTRALIA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 230
  • TABLE 399 AUSTRALIA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 230
  • TABLE 400 AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 231
  • TABLE 401 AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 231
  • TABLE 402 AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 231
  • TABLE 403 SINGAPORE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 232
  • TABLE 404 SINGAPORE MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 232
  • TABLE 405 SINGAPORE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 232
  • TABLE 406 SINGAPORE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 233
  • TABLE 407 SINGAPORE ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 233
  • TABLE 408 SINGAPORE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 233
  • TABLE 409 SINGAPORE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 233
  • TABLE 410 SINGAPORE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 234
  • TABLE 411 SINGAPORE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 234
  • TABLE 412 SINGAPORE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 234
  • TABLE 413 SINGAPORE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 234
  • TABLE 414 SINGAPORE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 235
  • TABLE 415 SINGAPORE EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 235
  • TABLE 416 SINGAPORE DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 235
  • TABLE 417 SINGAPORE CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 235
  • TABLE 418 SINGAPORE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 236
  • TABLE 419 SINGAPORE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 236
  • TABLE 420 SINGAPORE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 236
  • TABLE 421 THAILAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 237
  • TABLE 422 THAILAND MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 237
  • TABLE 423 THAILAND ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 237
  • TABLE 424 THAILAND ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 238
  • TABLE 425 THAILAND ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 238
  • TABLE 426 THAILAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 238
  • TABLE 427 THAILAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 238
  • TABLE 428 THAILAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 239
  • TABLE 429 THAILAND STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 239
  • TABLE 430 THAILAND STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 239
  • TABLE 431 THAILAND STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 239
  • TABLE 432 THAILAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 240
  • TABLE 433 THAILAND EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 240
  • TABLE 434 THAILAND DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 240
  • TABLE 435 THAILAND CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 240
  • TABLE 436 THAILAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 241
  • TABLE 437 THAILAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 241
  • TABLE 438 THAILAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 241
  • TABLE 439 MALAYSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 242
  • TABLE 440 MALAYSIA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 242
  • TABLE 441 MALAYSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 242
  • TABLE 442 MALAYSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 243
  • TABLE 443 MALAYSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 243
  • TABLE 444 MALAYSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 243
  • TABLE 445 MALAYSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 243
  • TABLE 446 MALAYSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 244
  • TABLE 447 MALAYSIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 244
  • TABLE 448 MALAYSIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 244
  • TABLE 449 MALAYSIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 244
  • TABLE 450 MALAYSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 245
  • TABLE 451 MALAYSIA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 245
  • TABLE 452 MALAYSIA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 245
  • TABLE 453 MALAYSIA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND) 245
  • TABLE 454 MALAYSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 246
  • TABLE 455 MALAYSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 246
  • TABLE 456 MALAYSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 246
  • TABLE 457 INDONESIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 247
  • TABLE 458 INDONESIA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 247
  • TABLE 459 INDONESIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 247

LIST OF FIGURES

  • FIGURE 1 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: SEGMENTATION 49
  • FIGURE 2 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: DATA TRIANGULATION 52
  • FIGURE 3 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: DROC ANALYSIS 53
  • FIGURE 4 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 54
  • FIGURE 5 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 54
  • FIGURE 6 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 55
  • FIGURE 7 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: MARKET END USER COVERAGE GRID 57
  • FIGURE 8 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: DBMR MARKET POSITION GRID 58
  • FIGURE 9 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: VENDOR SHARE ANALYSIS 59
  • FIGURE 10 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: SEGMENTATION 62
  • FIGURE 11 THE RISING PREVALENCE AND IMPACT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) AND INTRODUCTION OF NOVEL THERAPIES FOR DMD DISORDER ARE EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET FROM 2023 TO 2030 63
  • FIGURE 12 MOLECULAR-BASED THERAPIES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET IN 2023 AND 2030 63
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET 71
  • FIGURE 14 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY TREATMENT TYPE , 2022 82
  • FIGURE 15 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND) 83
  • FIGURE 16 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY TREATMENT TYPE , CAGR (2023-2030) 83
  • FIGURE 17 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE 84
  • FIGURE 18 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY THERAPY, 2022 91
  • FIGURE 19 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY THERAPY, 2023-2030 (USD THOUSAND) 92
  • FIGURE 20 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY THERAPY, CAGR (2023-2030) 92
  • FIGURE 21 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY THERAPY, LIFELINE CURVE 93
  • FIGURE 22 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022 99
  • FIGURE 23 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND) 100
  • FIGURE 24 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030) 100
  • FIGURE 25 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE 101
  • FIGURE 26 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY END USER, 2022 106
  • FIGURE 27 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND) 107
  • FIGURE 28 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY END USER, CAGR (2023-2030) 107
  • FIGURE 29 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY END USER, LIFELINE CURVE 108
  • FIGURE 30 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022 114
  • FIGURE 31 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 115
  • FIGURE 32 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 115
  • FIGURE 33 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 116
  • FIGURE 34 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET SNAPSHOT 122
  • FIGURE 35 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: COMPANY SHARE 2022 (%) 305
  • FIGURE 36 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: COMPANY SHARE 2022 (%) 306
  • FIGURE 37 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: COMPANY SHARE 2022 (%) 307
  • FIGURE 38 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: COMPANY SHARE 2022 (%) 308